Virology News and Research

Latest Virology News and Research

Georgia Tech/CDC project focuses on microneedle patches for polio vaccination

Mark Prausnitz, Regents' professor in Georgia Tech's School of Chemical and Biomolecular Engineering, will pursue an innovative global health research project focused on using microneedle patches for the low-cost administration of polio vaccine through the skin in collaboration with researchers Steve Oberste and Mark Pallansch of the US Centers for Disease Control and Prevention.

8 Nov 2011

MBL-HCV1 can reduce viral load in liver transplant patients

A human monoclonal antibody developed by MassBiologics of the University of Massachusetts Medical School (UMMS) given to patients with chronic hepatitis C virus (HCV) infection undergoing liver transplantation significantly suppressed the virus for at least a week after transplant and delayed the time to viral rebound.

8 Nov 2011

Economic burden of chronic hepatitis C-related liver disease

Health care costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study.

8 Nov 2011

Beware mail order Chicken pox warn Doctors

Doctors have warned against a new trend that has emerged via social networking websites like Facebook - one that guides parents through a process of exposing their children to chicken pox, so that they can get the virus, early and avoid any need for vaccination.

7 Nov 2011

Encouraging results from SEEK's FLU-v Phase II study

SEEK, a leading UK privately-owned drug-discovery group, today announced encouraging results following the successful completion of its Universal Flu Vaccine Phase II challenge study.

7 Nov 2011

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naïve patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA, USA.

7 Nov 2011

Study provides blueprint for design of new HIV drugs

Scientists have moved a step closer to understanding how one of our body's own proteins helps stop the human immunodeficiency virus (HIV-1) in its tracks.

7 Nov 2011

MRSA co-infection increases risk of flu-related mortality among children

During the 2009 H1N1 influenza pandemic, many previously healthy children became critically ill, developing severe pneumonia and respiratory failure, sometimes fatal. The largest nationwide investigation to date of influenza in critically ill children, led by Children's Hospital Boston, found one key risk factor: Simultaneous infection with methicillin-resistant Staphylococcus aureus (MRSA) increased the risk for flu-related mortality 8-fold among previously healthy children.

7 Nov 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex Pharmaceuticals Incorporated today announced positive interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with chronic genotype 1 hepatitis C (HCV) and human immunodeficiency virus.

7 Nov 2011

Researchers discover two effective cancer killers

Researchers at the University of Southern California have identified two molecules that may be more effective cancer killers than are currently available on the market.

7 Nov 2011

New data from Santaris Pharma miravirsen Phase 2a trial on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, presents new data from the Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was maintained for more than four weeks beyond the end of therapy.

6 Nov 2011

Guardian profiles Anglo American CMO's efforts to fight HIV/AIDS

The Guardian profiles Brian Brink, chief medical officer at Anglo American, South Africa's largest private-sector employer, and the company's efforts to treat and prevent HIV among its employees.

5 Nov 2011

HIV and AIDS do not discriminate

They don't discriminate. They can affect the young, older adults and pregnant women. They also strike rich and poor, male and female. People from all walks of life can become infected with HIV and AIDS. Knowing how to prevent them, how to live with them, and the strides made over the years to fight them are essential. This knowledge is one of the main goals of World AIDS Day, which is observed on December 1 each year.

5 Nov 2011

Misconceptions affecting participation in HIV vaccine trials

On December 1st, World AIDS Day 2011 will be observed in many countries around the globe. The theme of this year's World AIDS Day is "Getting to Zero"—specifically, zero new HIV infections, zero discrimination and zero AIDS-related deaths.

5 Nov 2011

International research explains why measles virus spreads so quickly

An international collaboration involving Inserm has revealed how the measles virus leaves the body of an infected person to contaminate another individual. The researchers have identified a key receptor, located in the trachea, which allows the virus to spread through the air rapidly from one organism to another. The receptor, nectine-4, is also known to be a biomarker for some cancers.

5 Nov 2011

Angolan health officials on high alert after polio case confirmed

Health officials in the northern Angolan province of Uige are on high alert "after a 14-month-old boy tested positive for polio, which has made a resurgence in the country, UNICEF said Thursday," Agence France-Presse reports (11/3).

5 Nov 2011

Study: Birth cohort screening for HCV is cost effective in primary care setting

According to a new study being published early online in Annals of Internal Medicine, the flagship journal of the American College of Physicians, birth cohort screening for hepatitis C is cost effective in the primary care setting.

5 Nov 2011

Active ingredient in saffron shows promise against MS

Medical researchers at the University of Alberta have discovered that an active ingredient in the Persian spice saffron may be a potential treatment for diseases involving neuroinflammation, such as multiple sclerosis.

5 Nov 2011

Study finds increase in cervical cancer incidence among young British women

The incidence of cervical cancer in women in their 20s has risen by over 40 per cent between 1992 and 2006 in England, despite the overall incidence of cervical cancer dropping by 30 per cent, according to research that will be presented at the annual National Cancer Research Institute (NCRI) Cancer Conference in Liverpool which starts tomorrow.

5 Nov 2011

Viewpoints: Romney's plan to cut the debt; congressional squabbles on spending; spurning insurers' concerns about new labels

First, eliminate every government program that is not absolutely essential. There are many things government does that we may like but that we do not need. … For example: Repeal ObamaCare, which would save $95 billion in 2016. …Eliminate Title X family planning programs benefiting abortion groups like Planned Parenthood. … Second, return federal programs to the states where innovation, cost management and reduction of fraud and abuse can far exceed what Washington achieves. I will block grant Medicaid and workforce training, saving well over $100 billion in 2016.

5 Nov 2011